CSL Limited (ASX: CSL) shares experienced a sharp decline following the announcement of its FY25 results and a significant restructuring plan, raising questions about the company’s future prospects. The market reacted strongly to the news, triggering a reassessment of the healthcare giant’s valuation.
CSL Price Targets
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
On August 19, CSL shares plummeted 15%, marking the company’s worst trading session since its listing in 1999, following the release of its FY25 results. The stock closed below $210 on Friday, September 5, a considerable drop from its 52-week high of $307.16. This decline reflects market concerns about the implications of the announced strategic changes.
The FY25 results revealed a 14% increase in annual profit. However, the healthcare giant announced a plan to spin off its vaccine division, Seqirus, and reduce its workforce by approximately 3,000 employees, representing about 15% of its staff outside the U.S. plasma unit. The company projects revenue growth of 4-5% and an underlying net profit after tax and amortization (NPATA) between $3.45 billion and $3.55 billion for FY26. The company also declared a final dividend of $1.62 per share, up from $1.45 per share the previous year.
Analysts have offered varied perspectives on the firms’s recent moves. JP Morgan cut its price target from $305 to $282, citing delays in the company’s cost reduction program and uncertainties surrounding the Seqirus spin-off. “We view CSL as attractively valued and retain our Overweight rating,” JP Morgan noted in its research report on August 20, despite these concerns. Macquarie retained an “Outperform” rating with a 12-month price target of $295.90, suggesting the market’s reaction was overblown. Other analysts have price targets ranging from $291.35 to $300, generally viewing CSL as a buying opportunity.
CSL’s forward price-to-earnings (P/E) ratio currently stands at approximately 19.07, below its historical average of around 32. The planned demerger of Seqirus and a $750 million share buyback program are expected to influence near-term performance, introducing both opportunities and uncertainties for the markets to consider.
Analyst Summary
Bull Case
- Undervalued based on historical P/E ratio.
- Analysts see significant upside potential.
- Core plasma business remains strong.
Bear Case
- Seqirus spin-off creates uncertainty.
- Cost reduction benefits delayed.
- Workforce reduction may impact productivity.
The market’s reaction to CSL’s restructuring highlights the sensitivity to strategic shifts and their potential impact on future earnings, but analyst sentiment remains cautiously optimistic, suggesting a possible recovery if the company executes its plans effectively.
Don’t Buy Just Yet
You will want to see this before you make any decisions.
Before you decide which shares to add to your portfolio you might want to take a look at this special report we recently published.
Our experts picked out The 5 best ASX shares to buy in 2025.
We’re giving away this valuable research for FREE.
Click below to secure your copy
